JP4875606B2 - ストレプトミセスから得られたワクチン組成物 - Google Patents
ストレプトミセスから得られたワクチン組成物 Download PDFInfo
- Publication number
- JP4875606B2 JP4875606B2 JP2007503180A JP2007503180A JP4875606B2 JP 4875606 B2 JP4875606 B2 JP 4875606B2 JP 2007503180 A JP2007503180 A JP 2007503180A JP 2007503180 A JP2007503180 A JP 2007503180A JP 4875606 B2 JP4875606 B2 JP 4875606B2
- Authority
- JP
- Japan
- Prior art keywords
- streptomyces
- vaccine composition
- tuberculosis
- strain
- strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000187747 Streptomyces Species 0.000 title claims abstract description 43
- 229960005486 vaccine Drugs 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims description 15
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 31
- 239000000427 antigen Substances 0.000 claims abstract description 20
- 108091007433 antigens Proteins 0.000 claims abstract description 20
- 102000036639 antigens Human genes 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 208000035473 Communicable disease Diseases 0.000 claims abstract 3
- 241000187398 Streptomyces lividans Species 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 241000186359 Mycobacterium Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 241000187180 Streptomyces sp. Species 0.000 claims 2
- 241000187432 Streptomyces coelicolor Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 30
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 23
- 230000002238 attenuated effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 244000309464 bull Species 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002906 microbiologic effect Effects 0.000 description 4
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 229960002109 tuberculosis vaccine Drugs 0.000 description 4
- 206010062207 Mycobacterial infection Diseases 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
ストレプトミセス(野生株)
ヒト結核菌の抗原Apaを発現する組換えストレプトミセス
免疫原性の研究
動物:
この実験では、CENPALAB(キューバ)によって供給された8〜10週齢の雄のBalb/cマウスを使用した。
凍結乾燥された弱毒化生BCG。InterVax,Biological Limited社(カナダ)。
この実験では、遺伝子的に形質転換されていない株1326、及び遺伝子的に形質転換され、ヒト結核菌のApAタンパクを発現する株1326を使用した。
30匹のBalb/cマウスを10匹ずつ4つのグループに分けた(表1)。
ストレプトミセス リビダンス及びBCGのタンパク抽出物、並びにヒト結核菌の組換えApaタンパクをSDS−PAGEによって分離し(Laemmli A,UK.Nature 1970;227(6):680−685)、これらを、半乾燥システム(NovaBlot II、Pharmacia社(スウェーデン))を使用して、0.45mcmニトロセルロース膜にブロットした。
生体内分布の研究
動物:
この実験では、CENPALAB(キューバ)によって供給された8〜10週齢の雄のBalb/cマウスを使用した。
凍結乾燥された弱毒化生BCG。InterVax,Biological Limited社(カナダ)。
この実験では、遺伝子的に形質転換されていない株1326、及び遺伝子的に形質転換され、ヒト結核菌のApAタンパクを発現する株1326を使用した。
チャレンジ実験
動物:
この実験では、CENPALAB(キューバ)によって供給された8〜10週齢の雄のBalb/cマウスを使用した。
凍結乾燥された弱毒化生BCG。InterVax,Biological Limited社(カナダ)。
この実験では、遺伝子的に形質転換されていない株1326、及び遺伝子的に形質転換され、ヒト結核菌のApAタンパクを発現する株1326を使用した。
肺を解離させ、Ogawa培地中(Manual de la OXID.Cuarta Edicion.1981 Editado por OXID Limited,England)で平板培養し、37で28日間賠償した。培養期間終了後、CFUを計数し、肺組織のCFU数/mgを求めた。
グループ間の統計的比較は、クルスカル−ウォリス(Kruskal−Wallis)検定を用いて実施し、自由分布の多重比較検定を補完的な検定として使用した。
ミコバクテリウム感染症、特に結核に対するワクチンとしてこの種の株を使用する利点は、非病原性株を使用することであり、このことは生きた株をヒトに使用することを可能にし、このことは、十分な免疫原性及び防御のための免疫反応の十分な刺激を保証する。
Claims (11)
- ストレプトミセスの1種又は数種の野生株、或いは前記株に由来する突然変異株又は組換え株を有効成分として有し、さらに適当な添加剤を有することを特徴とするストレプトミセスから得られたワクチン組成物。
- ストレプトミセスの前記株が生きた株であることを特徴とする、請求項1に記載のワクチン組成物。
- ストレプトミセスの前記株が、ストレプトミセス リビダンス(Streptomyces lividans)、ストレプトミセス コエリコロール(Streptomyces coelicolor)及びストレプトミセス Sp.(Streptomyces Sp.)であることを特徴とする、請求項1及び2に記載のワクチン組成物。
- ストレプトミセスの前記組換え株が、1種又は数種の異種抗原を発現することを特徴とする、請求項1に記載のワクチン組成物。
- ストレプトミセスの前記組換え株が、ミコバクテリウムの1種又は数種の異種抗原を発現することを特徴とする、請求項4に記載のワクチン組成物。
- 感染症の予防又は治療のための請求項1から5のいずれかに記載のワクチン組成物。
- ミコバクテリアによって引き起こされる感染の予防又は治療のための請求項6に記載のワクチン組成物。
- 結核の予防又は治療のための請求項7に記載のワクチン組成物。
- 感染症の予防又は治療のためのワクチン組成物を製造するための請求項1から5のいずれかに記載されたストレプトミセス株の使用。
- ミコバクテリアによって引き起こされる感染の予防又は治療のためのワクチン組成物を製造するための請求項9に記載の使用。
- 結核の予防又は治療のためのワクチン組成物を製造するための請求項10に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2004-0051 | 2004-03-18 | ||
CU20040051A CU23460A1 (es) | 2004-03-18 | 2004-03-18 | Composiciones vacunales obtenidas a partir de streptomyces |
PCT/CU2005/000002 WO2005087259A1 (es) | 2004-03-18 | 2005-03-18 | Composiciones vacunales obtenidas a partir de streptomyces. |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007529432A JP2007529432A (ja) | 2007-10-25 |
JP4875606B2 true JP4875606B2 (ja) | 2012-02-15 |
Family
ID=40251560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503180A Expired - Fee Related JP4875606B2 (ja) | 2004-03-18 | 2005-03-18 | ストレプトミセスから得られたワクチン組成物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070292452A1 (ja) |
EP (1) | EP1743651B1 (ja) |
JP (1) | JP4875606B2 (ja) |
KR (1) | KR20070026454A (ja) |
CN (1) | CN1960751A (ja) |
AT (1) | ATE419868T1 (ja) |
AU (1) | AU2005221262A1 (ja) |
BR (1) | BRPI0508160A (ja) |
CA (1) | CA2559633C (ja) |
CU (1) | CU23460A1 (ja) |
DE (1) | DE602005012252D1 (ja) |
ES (1) | ES2323080T3 (ja) |
MX (1) | MXPA06010616A (ja) |
RU (1) | RU2006136806A (ja) |
WO (1) | WO2005087259A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102100431B1 (ko) * | 2018-09-11 | 2020-04-13 | 한국해양과학기술원 | 스트렙토미세스로부터 유래된 새로운 화합물 및 용도 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8315579D0 (en) * | 1983-06-07 | 1983-07-13 | Biogen Nv | Streptomyces expression systems |
US6537558B2 (en) * | 1997-03-31 | 2003-03-25 | Megan Health, Inc. | Methods of producing and using virulence attenuated poxR mutant bacteria |
EP0962532A1 (en) * | 1998-06-03 | 1999-12-08 | Innogenetics N.V. | Polypeptides and nucleic acids encoding the same for the diagnosis and prevention of tuberculosis disease. |
JP2005538923A (ja) * | 2001-11-14 | 2005-12-22 | ノババックス インコーポレイテッド | ミコバクテリアワクチン |
KR100474111B1 (ko) * | 2001-12-26 | 2005-03-10 | 한국생명공학연구원 | 스트렙토마이세스 속 amlk-335 균주 및 그 생산화합물의 용도 |
-
2004
- 2004-03-18 CU CU20040051A patent/CU23460A1/es unknown
-
2005
- 2005-03-18 AU AU2005221262A patent/AU2005221262A1/en not_active Abandoned
- 2005-03-18 MX MXPA06010616A patent/MXPA06010616A/es active IP Right Grant
- 2005-03-18 BR BRPI0508160-2A patent/BRPI0508160A/pt not_active IP Right Cessation
- 2005-03-18 EP EP05729588A patent/EP1743651B1/en not_active Not-in-force
- 2005-03-18 CN CNA2005800130466A patent/CN1960751A/zh active Pending
- 2005-03-18 US US10/593,225 patent/US20070292452A1/en not_active Abandoned
- 2005-03-18 KR KR1020067021156A patent/KR20070026454A/ko not_active Application Discontinuation
- 2005-03-18 DE DE602005012252T patent/DE602005012252D1/de active Active
- 2005-03-18 AT AT05729588T patent/ATE419868T1/de not_active IP Right Cessation
- 2005-03-18 JP JP2007503180A patent/JP4875606B2/ja not_active Expired - Fee Related
- 2005-03-18 RU RU2006136806/15A patent/RU2006136806A/ru not_active Application Discontinuation
- 2005-03-18 WO PCT/CU2005/000002 patent/WO2005087259A1/es active Search and Examination
- 2005-03-18 ES ES05729588T patent/ES2323080T3/es active Active
- 2005-03-18 CA CA2559633A patent/CA2559633C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE419868T1 (de) | 2009-01-15 |
WO2005087259A1 (es) | 2005-09-22 |
KR20070026454A (ko) | 2007-03-08 |
BRPI0508160A (pt) | 2007-08-07 |
CN1960751A (zh) | 2007-05-09 |
EP1743651B1 (en) | 2009-01-07 |
RU2006136806A (ru) | 2008-04-27 |
DE602005012252D1 (de) | 2009-02-26 |
US20070292452A1 (en) | 2007-12-20 |
ES2323080T3 (es) | 2009-07-06 |
JP2007529432A (ja) | 2007-10-25 |
CU23460A1 (es) | 2009-12-01 |
EP1743651A1 (en) | 2007-01-17 |
CA2559633C (en) | 2011-09-06 |
CA2559633A1 (en) | 2005-09-22 |
MXPA06010616A (es) | 2007-07-04 |
AU2005221262A1 (en) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goodwin et al. | Brucellosis vaccines for livestock | |
Barrow | Salmonella infections: immune and non-immune protection with vaccines | |
Acevedo et al. | Bacterial outer membrane vesicles and vaccine applications | |
Chan et al. | Immune mechanisms of protection | |
Schurig et al. | Brucellosis vaccines: past, present and future | |
Mäkelä | Vaccines, coming of age after 200 years | |
Zepp | Principles of vaccination | |
JP4537178B2 (ja) | 多くの細胞外生成物及びそれらの製造法並びに使用 | |
US8512694B2 (en) | Method of producing rough strains of bacteria and uses thereof | |
Evensen | Immunization strategies against Piscirickettsia salmonis infections: Review of vaccination approaches and modalities and their associated immune response profiles | |
CN106102768B (zh) | 分枝杆菌抗原组合物 | |
Gheorgiu | Antituberculosis BCG vaccine: lessons from the past | |
Buddle | Vaccination of cattle against Mycobacterium bovis | |
JP4982009B2 (ja) | ナイセリアワクチン組成物および方法 | |
Cai et al. | Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection | |
Lopez et al. | Safety and immunogenicity of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen Rhodococcus equi | |
CN1437479B (zh) | 重组胞内病原体疫苗和使用方法 | |
JP4875606B2 (ja) | ストレプトミセスから得られたワクチン組成物 | |
JP2001512435A (ja) | 豊富な細胞外産物ならびにそれらの産生および使用方法 | |
TWI257867B (en) | Vaccine preparations containing attenuated toxin | |
Xing et al. | Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo | |
Chung et al. | Albert Léon Charles Calmette (1863-1933) and the antituberculous BCG vaccination | |
James | Induction of protective immunity against Schistosoma mansoni by a non‐living vaccine. V. Effects of varying the immunization and infection schedule and site | |
JP6867623B2 (ja) | 百日咳モデル動物およびその作製方法、ならびに百日咳モデル動物を用いた方法 | |
WO2013120159A1 (pt) | Cepa de mycobacterium recombinante, composição imunogênica e uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080303 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110404 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110411 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110502 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110512 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110603 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110629 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110906 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
R155 | Notification before disposition of declining of application |
Free format text: JAPANESE INTERMEDIATE CODE: R155 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111125 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141202 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |